BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Pozen Receives Not-Approvable Letter For MT 300; Stock Suffers
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Pozen Receives Not-Approvable Letter For MT 300; Stock Suffers
Oct. 21, 2003
By
Kim Coghill
No Comments
Pozen Inc.'s stock Monday took a major hit on news that the FDA rejected the firm's injectable migraine candidate because it failed to achieve statistical significance on secondary endpoints at the two-hour measuring point. (BioWorld Today)
BioWorld